Stock Ticker

  • Loading stock data...

Gilead Sciences, Inc. (NASDAQ:GILD): Beat Analyst’s Estimate

Boston, MA 04/25/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD)’s Sovaldi reported sales of $2.27 billion in the first quarter ended in March 31, 2014. The Company’s $1,000 pill has made a significant increase in sales and beat the average estimates of ~$1 billion. The shares of Gilead rose by 39% in last 12 months, and last […]

Gilead Sciences, Inc. (NASDAQ:GILD) Aims To High Growth HIV Generics

Boston, MA 04/23/2014 (wallstreetpr) – The U.S. Food and Drug Administration (FDA) have accepted the refiling of Gilead Sciences, Inc. (NASDAQ:GILD)’s two new drug applications (NDA) for cobicistat and elvitegravir to treat HIV. In 2012, Gilead submitted the NDA for these molecules, but the application was rejected by the FDA due to lack of sufficient information. […]

Bristol-Myers Squibb Co (NYSE:BMY) Unveils A New Combination To Fight HIV

Boston, MA 04/17/2014 (wallstreetpr) – Bristol-Myers Squibb Co (NYSE:BMY) said that it has filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval of a combination that combines its HIV treatment vaccine called Reyataz whose chemical name is Atazanavir Sulfate and Gilead Sciences, Inc. (NASDAQ:GILD) Cobicistat for treating the HIV […]

Natco Opposing Gilead Sciences, Inc. (NASDAQ:GILD) Hepatitis C drug Patent Application in India

Boston, MA 04/10/2014 (wallstreetpr) – Reports in India indicate that Natco has formally asked the patent office in India, to deny U.S Gilead Sciences, Inc. (NASDAQ:GILD) patent for its Hepatitis C drug Sovaldi. The move if successful, would clear path for the Indian government to launch a generic drug for the illness. Natco is filling a […]

Gilead Sciences, Inc. (NASDAQ:GILD)’s Hepatitis drug: Efficiency Over Affordability

Boston, MA 03/17/2014 (wallstreetpr) – Sovaldi from Gilead Sciences, Inc. (NASDAQ:GILD) expects to become one of the best-selling medicine to treat Hepatitis C virus (HCV). The successful launch of the product had significant impacts on company’s overall product sales. Market Around 2 million people in the U.S. suffer from Hepatitis C and the number will continue […]

Shareholder Breakfast: JPMorgan Chase & Co. (NYSE:JPM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Boston, MA 02/19/2014 (wallstreetpr) – JPMorgan Chase & Co. (NYSE:JPM) is mourning the death of yet another one of its bankers. The leading U.S. lender and global banking services provider started the week with the tragic death of one of its investment banker who plunged to death from the roof of its 30-storey headquarters in […]

Tuesday Stock Update: ArcelorMittal (ADR) (NYSE:MT), Verizon Communications Inc. (NYSE:VZ), Gilead Sciences, Inc. (NASDAQ:GILD)

Boston, MA 02/11/2014 (wallstreetpr) – ArcelorMittal (ADR) (NYSE:MT)’s rumored purchase bid for Ilva remains one of the top trending news in steel industry. Although some other names have also featured as also being interested in bidding for the troubled Ilva, a family owned steel giant in southern Europe. It is reported that Italian steel groups […]

Does Gilead Sciences Inc (NASDAQ:GILD) Prioritize Money Over Human Health?

Boston, MA 02/10/2014 (wallstreetpr) – Gilead Sciences Inc (NASDAQ:GILD) has made a name in the area of providing treatment solutions for people living with Hepatitis C. However, in the eyes of some people, GILD is benefiting a great deal by selling treatment for people suffering from Hepatitis C, at huge rates that shows the company […]

Hot Stocks to Watch Out For: Gilead Sciences, Inc. (NASDAQ:GILD), Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR), Yahoo! Inc. (NASDAQ:YHOO)

Boston, MA 02/10/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) had its stock price objective hoisted by analysts at RBC Capital. The analysts now have $96 price target, up from the previous target of $90 per share. This new price target reveals a significant potential upside on the stock considering that it is presently trading around […]

Gilead Sciences, Inc. (NASDAQ:GILD) Reports Good Results

Boston, MA 02/07/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD), the Foster City, CA-based biopharmaceutical company recently reported its fourth quarter results for 2013. It also announced its full EPS for 2013. With both of the results being reported as very good, Gilead Sciences should ideally have reported jump in prices. Unfortunately, it did not happen […]

Trending Stocks Today: Intel Corporation (NASDAQ:INTC), Gilead Sciences, Inc. (NASDAQ:GILD), Micron Technology, Inc. (NASDAQ:MU)

Boston, MA 02/06/2014 (wallstreetpr) – Intel Corporation (NASDAQ:INTC) is breaking into new grounds, and now it is all about bringing new possibilities into technology. The company has announced a new technology that would increase human-computer interaction. RealSense, a new technology which the chipmaker debuted this year, allows computers to understand human interactions like sight and […]

Buzzing Stocks: Boston Scientific Corporation (NYSE:BSX); Gilead Sciences, Inc. (NASDAQ:GILD) And PulteGroup, Inc. (NYSE:PHM)

Boston, MA 02/04/2014 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) is set to announce its fourth quarter results today. In the last few years, BSX has missed to report any improvement in its revenues due to fierce competition and pricing pressure. But, the company’s effective cost cutting results and recent developments happening at the company’s two […]

European Commission Approves Of Gilead Sciences Inc. (NASDAQ:GILD)’s Hepatits C Drug

Boston, MA 01/23/2014 (wallstreetpr) – Gilead Sciences Inc. (NASDAQ:GILD) announced on Jan 17 that its new drug to treat Hepatitis C was approved and will be soon launched across the European Union. The drug Sovaldi had in November earlier received a favorable recommendation from the European Medicines Agency, after which the European Commission has now […]

Gilead Sciences, Inc. (NASDAQ:GILD) announces its third quarter results

Gilead Sciences, Inc. (NASDAQ:GILD) has announced its financial results for the third quarter, where the company’s non-GAAP EPS was $0.52 per share which can be compared to $0.50 per share during the same quarter last year. Its product sales globally were in excess of $2.7 billion, which was 15 per cent better than the same […]

Gilead Sciences, Inc. (NASDAQ:GILD) Gets A HIV Boost

Boston, MA 10/31/2013 (wallstreetpr) – Hundred Billion Dollar Biopharmaceutical Company Gilead Sciences, Inc. (NASDAQ:GILD) has come out with stellar results which look to have received a booster shot from sale of its HIV drugs. Company has been able to increase its revenues by 15% to $2.78 billion. This is almost 60 million dollars more than what analysts […]

Sign Up To Get Our Latest Stocks Alerts